The Motley Fool··Emma NewberyNovo Nordisk Shares Slide on CagriSema Trial Results
Novo Nordisk shares fell 16% after CagriSema obesity drug trial underperformed rival Eli Lilly's tirzepatide. Deutsche Bank downgraded the stock amid competitive concerns.
LLYNVSNVOweight losstirzepatide